VONVENDI Approved for Prophylaxis

The FDA has expanded the indication for VONVENDI, a recombinant von Willebrand factor replacement therapy. It is now approved for prophylactic treatment for adults with type 1 and type 2 VWD.

Source: National Bleeding Disorders Foundation, NBDF Notes, September 2025